Diagnostic and prognostic markers in gliomas-an update

British Journal of Neurosurgery

Volumn 27, Issue 3, 2013, Pages 311-315

  Ma, R ^a   De Pennington, N ^a   Hofer, M ^a   Blesing, C ^b   Stacey, R ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

1p19q; Biomarker; Glioma; IDH1; MGMT; Prognosis

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT CHEMORADIOTHERAPY; ASTROCYTOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME MUTATION; DNA METHYLATION; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; GLIOSIS; HUMAN; MEDULLOBLASTOMA; MISSENSE MUTATION; NEUROEPITHELIOMA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; REVIEW; TUMOR DIAGNOSIS;

ADULT; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMOSOME DELETION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENETIC MARKERS; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR SUPPRESSOR PROTEINS;

EID: 84877300095     PISSN: 02688697     EISSN: 1360046X     Source Type: Journal    
DOI: 10.3109/02688697.2012.752432     Document Type: Review

References (39)

1. Reifenberger J, Reifenberger G, Liu L, e t al . Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p . Am J Pathol 1994 ; 145 : 1175 - 90 . PubMed PMID: 7977648. Pubmed Central PMCID: PMC1887413. eng (Pubitemid 24345665)
2. Cairncross JG, Ueki K, Zlatescu MC, e t al . Specifi c genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas . J Natl Cancer Inst 1998; 90 : 1473 - 9 . PubMed PMID: 9776413. eng (Pubitemid 28482012)
3. Jenkins RB, Blair H, Ballman KV, et al . A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma . Cancer Res 2006; 66: 9852- 61. PubMed PMID: 17047046. eng (Pubitemid 44672036)
4. C airncross G, J enkins R. G liomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 2008; 14 : 352 - 7 . PubMed PMID: 19060598. eng
5. Idbaih A, Marie Y, Lucchesi C, et al . B AC array CGH distinguishes mutually exclusive alterations that defi ne clinicogenetic subtypes of gliomas . Int J Cancer 2008; 122 : 1778 - 86 . PubMed PMID: 18076069. eng (Pubitemid 351413424)
6. Maintz D, Fiedler K, Koopmann J, et al . Molecular genetic evidence for subtypes of oligoastrocytomas . J Neuropathol Exp Neurol 1997; 56: 1098- 104. PubMed PMID: 9329453. eng (Pubitemid 27430471)
7. v an den Bent M J, C arpentier A F, B randes A A, e t al . Adjuvant procarbazine, lomustine, and vincristine improves progressionfree survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ha se III trial. J Clin Oncol 2006; 24 : 2715 - 22 . PubMed PMID: 16782911. eng (Pubitemid 46630567)
8. Kaloshi G, Benouaich-Amiel A, Diakite F, e t al . Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome . Neurology 2007; 68 : 1831 - 6 . PubMed PMID: 17515545. eng (Pubitemid 46791397)
9. Cairncross G, Berkey B, Shaw E, e t al. P hase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Th erapy Oncology Group Trial 9402 . J Clin Oncol 2006; 24 : 2707 - 14 . PubMed PMID: 16782910. eng (Pubitemid 46630566)
10. K aloshi G, E verhard S, L aigle-Donadey F, e t al . Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 2008; 70: 590- 5. PubMed PMID: 18285534. eng (Pubitemid 351294636)
11. Panageas KS, Iwamoto FM, Cloughesy TF, et al . Initial treatment patterns over time for anaplastic oligodendroglial tumors . Neuro Oncol 2012 ; 14 : 761 - 7 . PubMed PMID: 22661585. Pubmed Central PMCID: PMC3367843. eng
12. A brey L E, L ouis D N, P aleologos N, e t al . Survey of treatment recommendations for anaplastic oligodendroglioma . Neuro Oncol 2007 ; 9 : 314 - 8 . PubMed PMID: 17435180. Pubmed Central PMCID: PMC1907408. eng (Pubitemid 47169664)
13. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia . Cancer Res 1999; 59 : 793 - 7 . PubMed PMID: 10029064. eng (Pubitemid 29086728)
14. Hegi ME, Diserens AC, Gorlia T, et al . MGMT gene silencing and benefi t from temozolomide in glioblastoma . N Engl J Med 2005; 352: 997- 1003. PubMed PMID: 15758010. eng (Pubitemid 40349502)
15. Gerson SL . MGMT: its role in cancer aetiology and cancer therapeutics . Nat Rev Cancer 2004; 4 : 296 - 307 . PubMed PMID: 15057289. eng (Pubitemid 38525285)
16. Esteller M, Garcia-Foncillas J, Andion E, e t al . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents . N Engl J Med 2000; 343 : 1350 - 4 . PubMed PMID: 11070098. eng
17. Everhard S, Kaloshi G, Crini è re E, e t al . MGMT methylation: a marker of response to temozolomide in low-grade gliomas . Ann Neurol 2006; 60: 740- 3. PubMed PMID: 17192931. eng (Pubitemid 46048490)
18. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults . Clin Cancer Res 2009; 15: 330- 7. PubMed PMID: 19118062. eng
19. Komine C, Watanabe T, Katayama Y, e t al . Promoter hypermethylation of the DNA repair gene O6-methylguanine- DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diff use astrocytomas . Brain Pathol 2003; 13 : 176 - 84 . PubMed PMID: 12744471. eng (Pubitemid 36460818)
20. Stupp R, Mason WP, van den Bent MJ, e t al . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987- 96. PubMed PMID: 15758009. eng (Pubitemid 40349501)
21. Stupp R, Hegi ME, Mason WP, et al . Eff ects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial . Lancet Oncol 2009; 10: 459- 66. PubMed PMID: 19269895. eng
22. Krex D, Klink B, Hartmann C, e t al . Long-term survival with glioblastoma multiforme . Brain 2007; 130 : 2596 - 606 . PubMed PMID: 17785346. eng (Pubitemid 47511715)
23. Parsons DW, Jones S, Zhang X, e t al . An integrated genomic analysis of human glioblastoma multiforme . Science 2008 ; 321 : 1807 - 12 . PubMed PMID: 18772396. Pubmed Central PMCID: PMC2820389. eng
24. Balss J, Meyer J, Mueller W, e t al . A nalysis of the IDH1 codon 132 mutation in brain tumors . Acta Neuropathol 2008; 116 : 597 - 602 . PubMed PMID: 18985363. eng
25. Yan H, Parsons DW, Jin G, e t al . I DH1 and IDH2 mutations in gliomas . N Engl J Med 2009 ; 360 : 765 - 73 . PubMed PMID: 19228619. Pubmed Central PMCID: PMC2820383. eng
26. von Deimling A, Korshunov A, Hartmann C . Th e next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations . Brain Pathol 2011; 21 : 74 - 87 . PubMed PMID: 21129061. eng
27. Zhao S, Lin Y, Xu W, et al. G lioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261- 5. PubMed PMID: 19359588. eng
28. Dang L, White DW, Gross S, e t al . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate . Nature 2009 ; 462 : 739 - 44 . PubMed PMID: 19935646. Pubmed Central PMCID: PMC2818760. eng
29. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specifi c for IDH1 R132H mutation . Acta Neuropathol 2009; 118: 599- 601. PubMed PMID: 19798509. eng
30. Capper D, Reuss D, Schittenhelm J, e t al . Mutationspecific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology . Acta Neuropathol 2011; 121 : 241 - 52 . PubMed PMID: 21069360. eng
31. Sanson M, Marie Y, Paris S, e t al. I socitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150- 4. PubMed PMID: 19636000. eng
32. Hartmann C, Hentschel B, Wick W, e t al . Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1- mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic eff ect of higher age: implications for classifi cation of gliomas . Acta Neuropathol 2010; 120 : 707 - 18 . PubMed PMID: 21088844. eng
33. van den Bent MJ, Dubbink HJ, Marie Y, et al . IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group . Clin Cancer Res 2010; 16 : 1597 - 604 . PubMed PMID: 20160062. eng
34. Dubbink HJ, Taal W, van Marion R, et al . IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide . Neurology 2009; 73 : 1792 - 5 . PubMed PMID: 19933982. eng
35. Houillier C, Wang X, Kaloshi G, e t al. I DH1 or IDH2 mutations predict longer survival and response to temozolomide in lowgrade gliomas . Neurology 2010; 75 : 1560 - 6 . PubMed PMID: 20975057. eng
36. Labussi è re M, Idbaih A, Wang XW, e t al . All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 . Neurology 2010; 74 : 1886 - 90 . PubMed PMID: 20427748. eng
37. Seltzer MJ, Bennett BD, Joshi AD, et al . Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1 . Cancer Res 2010; 70: 8981- 7. PubMed PMID: 21045145. eng
38. Pfi ster S, Janzarik WG, Remke M, e t al . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in lowgrade astrocytomas . J Clin Invest 2008 ; 118 : 1739 - 49 . PubMed PMID: 18398503. Pubmed Central PMCID: PMC2289793. eng (Pubitemid 351632377)
39. J ones D T, K ocialkowski S, L iu L, e t al . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas . Cancer Res 2008 ; 68 : 8673 - 7 . PubMed PMID: 18974108. Pubmed Central PMCID: PMC2577184. eng